NEW INDICATIONS

Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 12, 2021, the FDA approved the combination of abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20%, as determined by an FDA-approved test. Abemaciclib is the first CDK4/6 inhibitor to receive FDA approval for adjuvant treatment of breast cancer.

On the same day, the FDA also approved the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) assay as a companion diagnostic test for selecting appropriate patients for this combination therapy.

This approval was based on the monarchE study, a randomized, open-label, 2-cohort multicenter clinical trial. The study included women and men with HR-positive, HER2-negative, node-positive, resected, early breast cancer and clinical and pathological features consistent with a high risk for disease recurrence. Patients were randomized in a 1 to 1 ratio to 2 years of abemaciclib plus their physician’s choice of endocrine therapy or to endocrine therapy alone.

The primary end point was invasive disease-free survival (IDFS). In the 2003 patients with high risk for disease recurrence and Ki-67 score ≥20%, the use of abemaciclib plus endocrine therapy showed significant improvement in IDFS (hazard ratio, 0.626; 95% confidence interval [CI], 0.488-0.803; P = .0042) versus endocrine therapy alone. At 36 months, the IDFS was 86.1% (95% CI, 82.8-88.8) with abemaciclib plus endocrine therapy compared with 79.0% (95% CI, 75.3-82.3) with endocrine therapy alone. The overall survival data were not mature at the time of the analysis.

The most common (≥20%) side effects were diarrhea, infections, neutropenia, fatigue, leukopenia, nausea, anemia, and headache.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: